Drug Discovery is transforming: economic pressures on drug design and development continue to accelerate the shift to in-silico first approaches, and cloud computing offers the unprecedented flexibility and scalability to power such solutions. As a result, researchers can leverage the predictive powers of classical modeling and experimental data analysis to unlock therapeutic innovation more efficiently than ever. In this new era of digital continuity and collaboration, the lines between computational and medicinal chemistry are blurred. Dassault Systèmes BIOVIA brings it all together on the 3DEXPERIENCE® platform: the science of classical modeling, the predictive power of AI and the connection to research laboratories.
Seamless in-silico Workflows
At BIOVIA, we recognize that the transformation to in-silico first requires best-of-breed computational models. But most importantly, it requires the orchestration of these models in seamless workflows that deliver science. Many biopharmaceutical organizations are already moving from discrete classical modeling applications to more complete and unified solutions. To accelerate this transformation and deliver the best scientific outcomes, we are proud to announce a strategic partnership with the Cambridge Crystallographic Data Centre (CCDC). Through this partnership, Dassault Systèmes has secured the exclusive rights to distribute the CCDC GOLD docking application in the cloud, as part of the 3DEXPERIENCE platform.
Best-in-class Docking Software
By bringing to the platform a world-class partner such as CCDC, we are paving the way to the future of Drug Discovery. CCDC’s GOLD protein-ligand docking software identifies the binding modes of active molecules—supporting the life sciences industry with proven success in virtual screening and lead optimization. GOLD supports single, detailed, high-accuracy and virtual compound library docking into the binding site of target proteins. It then ranks and prioritizes the compounds by their likelihood of binding. GOLD is highly regarded within the molecular modeling community for its accuracy, reliability, flexibility and configurability. By integrating GOLD with BIOVIA’s industry-leading Therapeutics Design software, we are now providing a complete portfolio of therapeutics modeling technology on the 3DEXPERIENCE platform.
Fabrice is in strategy and business development at Dassault Systemes BIOVIA. He has 16 years of experience bringing new technologies to market. Prior to joining BIOVIA, he worked on the Internet of Things, artificial intelligence and augmented reality for a large semiconductor company. He holds an MBA from the University of Chicago Booth School of Business, and a Master of Science from Supelec.